RapidEye
Shares of Sana Biotechnology (NASDAQ:SANA) rallied 270% post-market on positive results from a study of the transplantation of its allogeneic primary islet cell therapy UP421 into a patient with type 1 diabetes without the use of immunosuppression.
The pancreatic cell